title: Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study.
abstract: BACKGROUND
  When venous thromboembolism (VTE) includes deep-vein thrombosis (DVT) and pulmonary embolism (PE), patients with acute traumatic spinal cord injury (SCI) have the highest incidence of VTE among all hospitalized groups, with PE the third most common cause of death. Although low-molecular-weight heparin (LMWH) outperforms low-dose unfractionated heparin (LDUH) in other patient populations, the evidence in SCI remains less robust.
  
  
  OBJECTIVE
  To determine whether the efficacy for LMWH shown in previous SCI surveillance studies (eg, routine Doppler ultrasound) would translate into real-world effectiveness in which only clinically evident VTE is investigated (ie, after symptoms or signs present).
  
  
  METHODS
  A retrospective cohort study was conducted of 90 patients receiving LMWH dalteparin (5,000 U daily) or LDUH (5,000 U twice daily) for VTE prophylaxis after acute traumatic SCI. The incidence of radiographically confirmed VTE was primarily analyzed, and secondary outcomes included complications of bleeding and heparin-induced thrombocytopenia.
  
  
  RESULTS
  There was no statistically significant association (p = 0.7054) between the incidence of VTE (7.78% overall) and the type of prophylaxis received (LDUH 3/47 vs dalteparin 4/43). There was no significant differences in complications, location of VTE, and incidence of fatal PE. Paraplegia (as opposed to tetraplegia) was the only risk factor identified for VTE.
  
  
  CONCLUSIONS
  There continues to be an absence of definitive evidence for dalteparin (or other LMWH) over LDUH as the choice for VTE prophylaxis in patients with SCI. Novel approaches to VTE prophylaxis are urgently required for this population, whose risk of fatal PE has not decreased over the last 25 years.
authors.affiliation: Division of Physical Medicine and Rehabilitation, Dalhousie University, Nova Scotia Rehabilitation Centre, Department of Medicine, Halifax, Nova Scotia, Canada.
authors.forename: Scott
authors.initials: S
authors.lastname: Worley
authors.forename: Christine
authors.initials: C
authors.lastname: Short
authors.forename: Jeff
authors.initials: J
authors.lastname: Pike
authors.forename: David
authors.initials: D
authors.lastname: Anderson
authors.forename: Jo-Anne
authors.initials: JA
authors.lastname: Douglas
authors.forename: Kara
authors.initials: K
authors.lastname: Thompson
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D015331:Cohort Studies; D017985:Dalteparin / Q000008:administration & dosage*; D005260:Female; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010264:Paraplegia / Q000401:mortality; D011782:Quadriplegia / Q000401:mortality; D012189:Retrospective Studies; D012307:Risk Factors; D013119:Spinal Cord Injuries / Q000401:mortality*; D054556:Venous Thromboembolism / Q000401:mortality* / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D006493:Heparin; D017985:Dalteparin